Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
One calcitriol dose transiently increases Helios(+)FoxP3(+) T cells and ameliorates autoimmune demyelinating disease.
Santhera and NIH collaborate to evaluate Catena® in primary progressive multiple sclerosis
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Alemtuzumab and multiple sclerosis: therapeutic application.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Keystone Symposium: Advances in the Knowledge and Treatment of Autoimmunity
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Spin-offs: Meet the structure specialists
Symptom changes in multiple sclerosis following psychological interventions: a systematic review.
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Oxidative modification of serum proteins in multiple sclerosis.
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
B cells and multiple sclerosis.
Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.

Pages